Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ezose Sciences and Hirosaki University to Collaborate in Glycomics Research

Published: Wednesday, May 02, 2012
Last Updated: Tuesday, May 01, 2012
Bookmark and Share
International study will focus on urologic cancers through use of Ezose’s GlycanMap® platform.

Ezose Sciences Inc. and Hirosaki University have announced that they have formed a collaboration in glycomics research to identify new biomarkers for use in predicting and monitoring the progression of prostate cancer and other urological cancers.

The research will examine serum and urine samples collected by Hirosaki clinical investigators from well-characterized patient and control populations in Japan.

Ezose will conduct the glycan analysis at its US laboratories using its proprietary GlycanMap® technology platform.

“This agreement marks another step that scientists at Ezose and in universities are taking together to improve our understanding of the role of glycans in health and disease,” said Hidehisa Asada, Ph.D., Vice President, Research & Development at Ezose.

Asada continued, “Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice.”

Chikara Ohyama, M.D., Ph.D., Professor and Chairman, Department of Urology at the Hirosaki University Graduate School of Medicine, said: “Glycomics is beginning to come into its own as a basic tool in biomedical research. We look forward to applying this new technology to unmet medical needs in managing urologic cancers through the complementary contributions of Ezose’s scientists and our own.”

Under terms of the agreement, Ezose is granted exclusive rights by Hirosaki University to develop and commercialize new biomarkers resulting from the collaboration.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ezose Sciences Receives Grant from Michael J. Fox Foundation
Foundation to apply Ezose’s Glycan Map technology to investigating the role of glycans in Parkinson’s disease.
Thursday, February 20, 2014
Ezose Sciences Enters Glycomics Research Agreement with Kyowa Hakko Kirin
Kyowa Hakko Kirin to Fund Projects Exploiting Ezose’s GlycanMap® technology.
Tuesday, January 29, 2013
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!